Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that paired higher-than-approved doses of risankizumab with extended follow-up and found high early skin clearance ...
Spurred by fed-up consumers, states are trying to curb spiraling prescription drug costs by assembling special public boards to investigate and regulate pricing.
Jul 22, 2024
0
30
For patients with moderate-to-severe Crohn's disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission at week 48, according to a study published in the ...
Jul 18, 2024
0
43
Academic researchers from King's College London have investigated the early effects of an immunosuppressant drug that could help clinicians with future personalized approaches for the treatment of psoriasis.
Feb 19, 2024
0
51
Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology.
Jan 11, 2023
0
57
